Treatment

• Riluzole

  • A sodium-channel blocker that inhibits glutamate release in the CNS and decreases glutamate excitotoxicity

  • Prolongs survival and slows functional decline in patients with ALS (on average, for 3 months) [1]

• Edaravone

  • A free radical scavenger

  • Has been shown to slow functional decline in some patients with ALS

• Sodium phenylbutyrate-taurursodiol [16][17]

  • A combination of sodium phenylbutyrate and taurursodiol (ursodeoxycholic acid conjugated with taurine)

  • Prolongs survival and slows functional decline in patients with ALS

• Multidisciplinary and symptomatic therapy

Rilouzole rilly helps treating Lou Gehrig disease

• Most patients die within 3–5 years

• 5-year-survival: 30%

• 10-year-survival: 10–20%

• Early bulbar and/or respiratory symptoms are associated with a worse prognosis